Demuris is unlocking the unexplored, complex, bioactive chemistry found in nature.
Our platform is revolutionizing the natural product drug pipeline, from discovery to the clinic.
The Demuris proprietary toolbox allows us to rapidly identify leads, and combines our synthetic biology capabilities to optimize these compounds for optimal therapeutic benefit.
Latest News
Demuris is Commercial Partner in MRC Grant to Newcastle University
1 September 2019
£800,000 grant for optimization of novel antibiotics targeting multidrug-resistant tuberculosis. Newcastle, UK – September 11, 2019 – Demuris Limited, a company focused on the discovery and
Demuris and Newcastle University enter into Funded Collaboration with Morningside Ventures
1 August 2019
Focused on the development of novel therapeutics for mitochondrial diseases. Newcastle, UK – 2 August 2019 – The Wellcome Centre for Mitochondrial Research (WCMR) at Newcastle
Innovate UK Grant to Fund Development of Novel Antibiotics for Drug Resistant TB Awarded to Demuris
1 May 2019
Demuris has secured a £342,160 grant from Innovate UK to continue the development of a novel class of antibiotics for the treatment of multi-drug resistant
